Literature DB >> 15731232

Identification of sites in adenovirus hexon for foreign peptide incorporation.

Hongju Wu1, Tie Han, Natalya Belousova, Victor Krasnykh, Elena Kashentseva, Igor Dmitriev, Manjula Kataram, Parameshwar J Mahasreshti, David T Curiel.   

Abstract

Adenovirus type 5 (Ad5) is one of the most promising vectors for gene therapy applications. Genetic engineering of Ad5 capsid proteins has been employed to redirect vector tropism, to enhance infectivity, or to circumvent preexisting host immunity. As the most abundant capsid protein, hexon modification is particularly attractive. However, genetic modification of hexon often results in failure of rescuing viable viruses. Since hypervariable regions (HVRs) are nonconserved among hexons of different serotypes, we investigated whether the HVRs could be used for genetic modification of hexon by incorporating oligonucleotides encoding six histidine residues (His6) into different HVRs in the Ad5 genome. The modified viruses were successfully rescued, and the yields of viral production were similar to that of unmodified Ad5. A thermostability assay suggested the modified viruses were stable. The His6 epitopes were expressed in all modified hexon proteins as assessed by Western blotting assay, although the intensity of the reactive bands varied. In addition, we examined the binding activity of anti-His tag antibody to the intact virions with the enzyme-linked immunosorbent assay and found the His6 epitopes incorporated in HVR2 and HVR5 could bind to anti-His tag antibody. This suggested the His6 epitopes in HVR2 and HVR5 were exposed on virion surfaces. Finally, we examined the infectivities of the modified Ad vectors. The His6 epitopes did not affect the native infectivity of Ad5 vectors. In addition, the His6 epitopes did not appear to mediate His6-dependent viral infection, as assessed in two His6 artificial receptor systems. Our study provided valuable information for studies involving hexon modification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731232      PMCID: PMC1075677          DOI: 10.1128/JVI.79.6.3382-3390.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

Review 1.  Adenoviral gene therapy.

Authors:  Stephan A Vorburger; Kelly K Hunt
Journal:  Oncologist       Date:  2002

2.  Adenoviral vectors--new insights.

Authors:  G R Nemerow
Journal:  Trends Microbiol       Date:  2000-09       Impact factor: 17.079

3.  Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres.

Authors:  C Matthews; G Jenkins; J Hilfinger; B Davidson
Journal:  Gene Ther       Date:  1999-09       Impact factor: 5.250

4.  Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.

Authors:  Valérie Molinier-Frenkel; Renée Lengagne; Florence Gaden; Saw-See Hong; Jeannine Choppin; Hanne Gahery-Ségard; Pierre Boulanger; Jean-Gérard Guillet
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

5.  A system for the propagation of adenoviral vectors with genetically modified receptor specificities.

Authors:  J T Douglas; C R Miller; M Kim; I Dmitriev; G Mikheeva; V Krasnykh; D T Curiel
Journal:  Nat Biotechnol       Date:  1999-05       Impact factor: 54.908

6.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells.

Authors:  M Kim; K R Zinn; B G Barnett; L A Sumerel; V Krasnykh; D T Curiel; J T Douglas
Journal:  Eur J Cancer       Date:  2002-09       Impact factor: 9.162

8.  Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells.

Authors:  M Bai; B Harfe; P Freimuth
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

9.  Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX.

Authors:  Igor P Dmitriev; Elena A Kashentseva; David T Curiel
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution.

Authors:  F K Athappilly; R Murali; J J Rux; Z Cai; R M Burnett
Journal:  J Mol Biol       Date:  1994-09-30       Impact factor: 5.469

View more
  36 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 4.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

Review 5.  Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.

Authors:  Qiana L Matthews
Journal:  Mol Pharm       Date:  2010-12-01       Impact factor: 4.939

6.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

7.  Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.

Authors:  Linlin Gu; Valentina Krendelchtchikova; Alexandre Krendelchtchikov; Anitra L Farrow; Cynthia A Derdeyn; Qiana L Matthews
Journal:  Virology       Date:  2015-10-23       Impact factor: 3.616

8.  Targeting of adenovirus serotype 5 pseudotyped with short fiber from serotype 41 to c-erbB2-positive cells using bispecific single-chain diabody.

Authors:  Elena A Kashentseva; Joanne T Douglas; Kurt R Zinn; David T Curiel; Igor P Dmitriev
Journal:  J Mol Biol       Date:  2009-03-13       Impact factor: 5.469

9.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

Review 10.  Adenovirus receptors and their implications in gene delivery.

Authors:  Anurag Sharma; Xiaoxin Li; Dinesh S Bangari; Suresh K Mittal
Journal:  Virus Res       Date:  2009-02-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.